IGM Biosciences Inc (IGMS)
8.85
-0.92
(-9.37%)
USD |
NASDAQ |
Nov 21, 16:00
8.75
-0.10
(-1.13%)
After-Hours: 20:00
IGM Biosciences Enterprise Value: 361.88M for Nov. 20, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 20, 2024 | 361.88M |
| November 19, 2024 | 348.50M |
| November 18, 2024 | 329.47M |
| November 15, 2024 | 344.34M |
| November 14, 2024 | 381.80M |
| November 13, 2024 | 444.24M |
| November 12, 2024 | 456.13M |
| November 11, 2024 | 547.11M |
| November 08, 2024 | 556.03M |
| November 07, 2024 | 635.71M |
| November 06, 2024 | 648.20M |
| November 05, 2024 | 722.53M |
| November 04, 2024 | 714.21M |
| November 01, 2024 | 745.72M |
| October 31, 2024 | 800.14M |
| October 30, 2024 | 827.49M |
| October 29, 2024 | 807.27M |
| October 28, 2024 | 841.16M |
| October 25, 2024 | 782.31M |
| October 24, 2024 | 722.86M |
| October 23, 2024 | 734.15M |
| October 22, 2024 | 818.57M |
| October 21, 2024 | 712.75M |
| October 18, 2024 | 775.17M |
| October 17, 2024 | 734.15M |
| Date | Value |
|---|---|
| October 16, 2024 | 623.58M |
| October 15, 2024 | 698.48M |
| October 14, 2024 | 779.93M |
| October 11, 2024 | 672.92M |
| October 10, 2024 | 606.94M |
| October 09, 2024 | 589.10M |
| October 08, 2024 | 646.17M |
| October 07, 2024 | 596.83M |
| October 04, 2024 | 697.30M |
| October 03, 2024 | 666.98M |
| October 02, 2024 | 637.25M |
| October 01, 2024 | 643.20M |
| September 30, 2024 | 764.47M |
| September 27, 2024 | 752.04M |
| September 26, 2024 | 684.41M |
| September 25, 2024 | 717.04M |
| September 24, 2024 | 745.51M |
| September 23, 2024 | 692.12M |
| September 20, 2024 | 702.21M |
| September 19, 2024 | 765.68M |
| September 18, 2024 | 731.28M |
| September 17, 2024 | 792.37M |
| September 16, 2024 | 683.23M |
| September 13, 2024 | 473.24M |
| September 12, 2024 | 419.26M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-156.95M
Minimum
Oct 31 2023
3.510B
Maximum
Feb 09 2021
920.09M
Average
556.39M
Median
Enterprise Value Benchmarks
| Moderna Inc | 7.348B |
| NovaBay Pharmaceuticals Inc | 2.745M |
| Palatin Technologies Inc | 15.49M |
| iBio Inc | 9.932M |
| Theriva Biologics Inc | -12.74M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -61.43M |
| Revenue (Quarterly) | 0.516M |
| Total Expenses (Quarterly) | 64.90M |
| EPS Diluted (Quarterly) | -1.01 |
| Profit Margin (Quarterly) | -11.91K% |
| Earnings Yield | -40.79% |
| Normalized Earnings Yield | -40.79 |